Maze Therapeutics (MAZE) Operating Leases (2024 - 2026)

Maze Therapeutics has reported Operating Leases for 3 years, with the latest figure at $17.6 million in Q1 2026.

• Quarterly Operating Leases fell 17.01% year-over-year to $17.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.6 million (down 17.01% YoY) and the FY2025 annual result came in at $18.5 million, down 15.84% from the prior year.
• Operating Leases eased to $17.6 million in Q1 2026 per MAZE's latest filing, from $18.5 million in the prior quarter.
• Over five years, Operating Leases peaked at $22.0 million in Q4 2024 and troughed at $17.6 million in Q1 2026.
• A 3-year average of $19.8 million and a median of $19.9 million in 2025 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2025 and 2026: Operating Leases dropped 15.84% in 2025, then slipped 17.01% in 2026.
• Over 3 years, Operating Leases stood at $22.0 million in 2024, then decreased by 15.84% to $18.5 million in 2025, then retreated by 5.18% to $17.6 million in 2026.
• According to Business Quant data, Operating Leases over the past three periods registered $17.6 million, $18.5 million, and $19.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.